Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Guangdong Hengrui Pharmaceutical is the lead sponsor of 31 current clinical trials in our China register. 18 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are SHR-2173, SHR-1139 and SHR-1819. The most-studied condition is Asthma.

ClinicalTrials.gov trials by status

Recruiting1858%
Not yet open723%
Active, closed619%

Trials by phase

Phase 21755%
Phase 1723%
Phase 3516%
Phase 2/326%

Clinical trials sponsored by Guangdong Hengrui Pharmaceutical

31 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients NCT06441812 · ClinicalTrials.gov ↗ · Eosinophilic Asthma Patients Drug: SHR-1703	Phase 2	Recruiting	2024-07	China
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis NCT07211542 · ClinicalTrials.gov ↗ · Moderate-to-severe Atopic Dermatitis Drug: SHR-1905	Phase 2	Recruiting	2025-11	China
Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis NCT07719530 · ClinicalTrials.gov ↗ · Psoriasis	Phase 2	Recruiting	2026-08	China
A Study of SHR-2173 in Participants With Primary IgA Nephropathy NCT07354932 · ClinicalTrials.gov ↗ · Primary IgA Nephropathy Drug: SHR-2173	Phase 2	Recruiting	2026-03	China
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy NCT07289763 · ClinicalTrials.gov ↗ · Primary Membranous Nephropathy Drug: SHR-2173	Phase 2	Recruiting	2025-12	China
Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia NCT07206758 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia Drug: SHR-2173	Phase 1	Recruiting	2025-11	China
A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD NCT07567872 · ClinicalTrials.gov ↗ · COPD Drug: HRS-9821	Phase 1	Recruiting	2026-07	China
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis NCT07309055 · ClinicalTrials.gov ↗ · Adolescents With Moderate-to-severe Atopic Dermatitis Drug: SHR-1819	Phase 3	Recruiting	2026-03	China
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis NCT07192939 · ClinicalTrials.gov ↗ · IPF and PPF	Phase 2	Recruiting	2025-10	China
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults NCT07749651 · ClinicalTrials.gov ↗ · Cutaneous Lupus Erythematosus(CLE)	Phase 1	Recruiting	2026-08	China
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） NCT05979051 · ClinicalTrials.gov ↗ · Eosinophilic Granulomatosis With Polyangiitis Drugs: Mepolizumab, SHR-1703	Phase 2/3	Recruiting	2023-11	China
A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis NCT07229742 · ClinicalTrials.gov ↗ · Active Lupus Nephritis Drug: SHR-2173	Phase 2	Recruiting	2025-11	China
Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps NCT07132827 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyps Drug: SHR-1905	Phase 3	Recruiting	2025-08	China
A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis NCT07688772 · ClinicalTrials.gov ↗ · Seasonal Allergic Rhinitis Drug: SHR-1819	Phase 3	Recruiting	2026-08	China
A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma NCT07098403 · ClinicalTrials.gov ↗ · Asthma	Phase 3	Recruiting	2025-09	China
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis NCT06554509 · ClinicalTrials.gov ↗ · Prurigo Nodularis Drug: SHR-1819	Phase 2/3	Recruiting	2024-09	China
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus NCT07299422 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 2	Recruiting	2026-04	China
A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease NCT07640451 · ClinicalTrials.gov ↗ · COPD Drug: HRS-9821	Phase 2	Recruiting	2026-07	China
Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma NCT06940700 · ClinicalTrials.gov ↗ · Asthma	Phase 2	Not yet open	2025-04	China
A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants NCT07701239 · ClinicalTrials.gov ↗ · Asthma With Eosinophilic Phenotype Drug: SHR-1703	Phase 1	Not yet open	2026-07	China
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis NCT07758075 · ClinicalTrials.gov ↗ · Plaque Psoriasis Drug: SHR-1139	Phase 2	Not yet open	2026-08	China
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum NCT07444684 · ClinicalTrials.gov ↗ · Pyoderma Gangrenosum Drug: SHR-1139	Phase 2	Not yet open	2026-03	China
A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-Severe Ulcerative Colitis NCT07758101 · ClinicalTrials.gov ↗ · Moderate to Severe Ulcerative Colitis	Phase 1	Not yet open	2026-08	China
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis NCT07622342 · ClinicalTrials.gov ↗ · Generalized Myasthenia Gravis Drug: SHR-2173	Phase 2	Not yet open	2026-06	China
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity NCT07826364 · ClinicalTrials.gov ↗ · Body Weight Management	Phase 1	Not yet open	2026-09	China
A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis NCT07233655 · ClinicalTrials.gov ↗ · Moderate to Severe Active Rheumatoid Arthritis	Phase 2	Active, closed	2026-01	China
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors NCT06993116 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Active, closed	2025-06	China
A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis NCT07321951 · ClinicalTrials.gov ↗ · Moderate-to-severe Atopic Dermatitis Drug: SHR-1819	Phase 2	Active, closed	2026-01	China
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma NCT06653322 · ClinicalTrials.gov ↗ · Asthma With Eosinophilic Phenotype	Phase 3	Active, closed	2024-11	China
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis NCT07232576 · ClinicalTrials.gov ↗ · Adult Patients With Moderately to Severely Active Ulcerative Colitis Drug: SHR-1139	Phase 2	Active, closed	2025-12	China
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis NCT06875934 · ClinicalTrials.gov ↗ · Moderate to Severe Plaque Psoriasis Drug: SHR-1139	Phase 2	Active, closed	2025-03	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Guangdong Hengrui Pharmaceutical trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

SHR-21735 SHR-11394 SHR-18194 SHR-17033 HRS-98212 SHR-19052 Mepolizumab1

Conditions in Guangdong Hengrui Pharmaceutical trials

27 conditions

Asthma2Asthma With Eosinophilic Phenotype2Moderate-to-severe Atopic Dermatitis2COPD2Eosinophilic Asthma Patients1Moderate to Severe Active Rheumatoid Arthritis1Psoriasis1 Plaque Psoriasis1Pyoderma Gangrenosum1Advanced Solid Tumor1Moderate to Severe Ulcerative Colitis1Generalized Myasthenia Gravis1Primary IgA Nephropathy1Primary Membranous Nephropathy1 Immune Thrombocytopenia1Adolescents With Moderate-to-severe Atopic Dermatitis1IPF and PPF1Cutaneous Lupus Erythematosus(CLE)1Eosinophilic Granulomatosis With Polyangiitis1Active Lupus Nephritis1Chronic Rhinosinusitis With Nasal Polyps1Adult Patients With Moderately to Severely Active Ulcerative Colitis1Body Weight Management1Seasonal Allergic Rhinitis1

By trial register

Register	Trials	Recruiting
Clinical trials in China	31	18

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Asthma

Sponsor	Trials
GlaxoSmithKline	11
Sanofi	6
Chiesi Farmaceutici	2
Teva Branded Pharmaceutical Products R&D	2
First Affiliated Hospital of Ningbo University	2
Sunshine Guojian Pharmaceutical (Shanghai)	2
Uniquity One (UNI)	1
Generate Biomedicines	1
Apogee Therapeutics	1
Enveda Therapeutics	1

Sponsors with the most current trials registered for this condition.

Questions about Guangdong Hengrui Pharmaceutical trials

How many clinical trials does Guangdong Hengrui Pharmaceutical sponsor?

Guangdong Hengrui Pharmaceutical is the lead sponsor of 31 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Guangdong Hengrui Pharmaceutical trials recruiting?

Yes. 18 of its 31 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Guangdong Hengrui Pharmaceutical testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are SHR-2173 (5), SHR-1139 (4), SHR-1819 (4), SHR-1703 (3) and HRS-9821 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Guangdong Hengrui Pharmaceutical clinical trials